NOVATO, CA--(Marketwire - February 23, 2009) -
WHAT:
Raptor Pharmaceuticals, San Francisco Bay Area biotech company, will
participate in Global Rare Disease Day on February 28, 2009, joining
hundreds of patient organizations, government agencies, medical societies
and other drug development companies to focus attention on Rare Diseases. A
Rare Disease affects fewer than 200,000 Americans, and nearly 7,000 such
diseases afflict nearly 30 million Americans, according to the National
Institutes of Health ("NIH").
Global Rare Disease Day website: www.rarediseaseday.org
Information on U.S. Rare Disease Day on the NORD website:
http://www.rarediseases.org/rare_disease_day/rare_disease_day_info
WHEN:
February 28, 2009
RESOURCES:
Sacramento / San Francisco Bay Area families active in the fight against
cystinosis, a rare genetic disorder
Researchers working towards a cure/improved treatment for cystinosis
Nephropathic cystinosis (cystinosis) is a serious lysosomal storage
disease, primarily diagnosed in early childhood. If left untreated,
cystinosis destroys major organ systems including the kidneys, eyes, liver,
muscles, pancreas and the brain. The current treatment, cysteamine therapy,
may be effective at preventing kidney failure by delaying kidney
transplants in cystinosis patients. However, patient compliance is
challenging due to frequent dosing and potential gastrointestinal side
effects.
http://www.raptorpharma.com/patients_cystinosis.html
Raptor Pharmaceuticals' DR Cysteamine product candidate is a
delayed-release oral formulation of cysteamine bitartrate currently being
investigated for its potential to improve the management of cystinosis by
potentially reducing frequency of dosing and minimizing gastrointestinal
side effects. http://www.raptorpharma.com/dr_cysteamine_cystinosis.html
About Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding the
delivery of new treatment options to patients by working to improve
existing therapeutics through the application of highly specialized drug
targeting platforms and formulation expertise. Raptor focuses on
underserved patient populations where it can have the greatest potential
impact. Raptor currently has product candidates in clinical development to
treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"),
Huntington's Disease ("HD") which is also a rare disease, and aldehyde
dehydrogenase ("ALDH2") deficiency.
Raptor's preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein ("RAP") and related proteins that are designed
to target cancer, neurodegenerative disorders and infectious diseases.
For additional information, please visit www.raptorpharma.com.
Contact Information: Contact:
The Ruth Group
Janine McCargo
646-536-7033